NYSE: ZTS |
| Healthcare / Drug Manufacturers / USA |
165.90 | +2.87 | +1.76% | Vol 1.59M | 1Y Perf -7.01% |
May 26th, 2022 16:04 DELAYED |
BID | 160.16 | ASK | 167.60 | ||
Open | 163.83 | Previous Close | 165.90 | ||
Pre-Market | - | After-Market | 165.90 | ||
- - | - -% |
Target Price | 244.78 | Analyst Rating | Strong Buy 1.21 | |
Potential % | 47.55 | Finscreener Ranking | ★★+ 47.43 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★ 45.42 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 63.87 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★★ 37.83 | |
Price Range Ratio 52W % | 9.97 | Earnings Rating | Sell | |
Market Cap | 78.08B | Earnings Date | 5th May 2022 | |
Alpha | 0.01 | Standard Deviation | 0.06 | |
Beta | 0.77 |
Today's Price Range 162.91166.57 | 52W Range 156.67249.27 | 5 Year PE Ratio Range 27.8072.90 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 2.05% | ||
1 Month | -7.04% | ||
3 Months | -14.80% | ||
6 Months | -24.36% | ||
1 Year | -7.01% | ||
3 Years | 62.01% | ||
5 Years | 164.97% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 38.60 | |||
ROE last 12 Months | 48.67 | |||
ROA (5Y Avg) | 7.36 | |||
ROA last 12 Months | 15.42 | |||
ROC (5Y Avg) | 15.20 | |||
ROC last 12 Months | 19.69 | |||
Return on invested Capital Q | 5.30 | |||
Return on invested Capital Y | 4.02 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 7.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
37.30 | ||||
16.42 | ||||
9.72 | ||||
36.40 | ||||
70.60 | ||||
4.46 | ||||
140.89 | ||||
9.90 | ||||
80.11B | ||||
Forward PE | 28.15 | |||
PEG | 3.16 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.40 | ||||
2.30 | ||||
0.54 | ||||
1.45 | ||||
12.50 | ||||
Leverage Ratio | 3.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
70.60 | ||||
34.80 | ||||
40.60 | ||||
28.40 | ||||
26.27 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
7.89B | ||||
16.77 | ||||
8.93 | ||||
8.86 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.80 | ||||
1.30 | ||||
21.19 | ||||
21.64 | ||||
Payout ratio | 22.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | 1.22 | 1.32 | 8.20 |
Q04 2021 | 0.96 | 1.00 | 4.17 |
Q03 2021 | 1.10 | 1.25 | 13.64 |
Q02 2021 | 1.08 | 1.19 | 10.19 |
Q01 2021 | 1.04 | 1.26 | 21.15 |
Q04 2020 | 0.86 | 0.91 | 5.81 |
Q03 2020 | 0.89 | 1.10 | 23.60 |
Q02 2020 | 0.66 | 0.89 | 34.85 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 1.22 | -7.58 | Negative |
9/2022 QR | 1.31 | -2.24 | Negative |
12/2022 FY | 5.06 | -1.75 | Negative |
12/2023 FY | 5.79 | -0.86 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 1.22 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | 11.80 |
Volume Overview | |
---|---|
Volume | 1.59M |
Shares Outstanding | 470.63K |
Shares Float | 470.35M |
Trades Count | 29.41K |
Dollar Volume | 263.06M |
Avg. Volume | 2.27M |
Avg. Weekly Volume | 2.09M |
Avg. Monthly Volume | 2.49M |
Avg. Quarterly Volume | 2.24M |
Zoetis Inc. Class A (NYSE: ZTS) stock closed at 165.9 per share at the end of the most recent trading day (a 1.76% change compared to the prior day closing price) with a volume of 1.59M shares and market capitalization of 78.08B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11300 people. Zoetis Inc. Class A CEO is Kristin C. Peck.
The one-year performance of Zoetis Inc. Class A stock is -7.01%, while year-to-date (YTD) performance is -32.02%. ZTS stock has a five-year performance of 164.97%. Its 52-week range is between 156.67 and 249.27, which gives ZTS stock a 52-week price range ratio of 9.97%
Zoetis Inc. Class A currently has a PE ratio of 37.30, a price-to-book (PB) ratio of 16.42, a price-to-sale (PS) ratio of 9.72, a price to cashflow ratio of 36.40, a PEG ratio of 2.32, a ROA of 15.42%, a ROC of 19.69% and a ROE of 48.67%. The company’s profit margin is 26.27%, its EBITDA margin is 40.60%, and its revenue ttm is $7.89 Billion , which makes it $16.77 revenue per share.
Of the last four earnings reports from Zoetis Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.22 for the next earnings report. Zoetis Inc. Class A’s next earnings report date is -.
The consensus rating of Wall Street analysts for Zoetis Inc. Class A is Strong Buy (1.21), with a target price of $244.78, which is +47.55% compared to the current price. The earnings rating for Zoetis Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Zoetis Inc. Class A has a dividend yield of 0.80% with a dividend per share of $1.30 and a payout ratio of 22.00%.
Zoetis Inc. Class A has a Sell technical analysis rating based on Technical Indicators (ADX : 9.02, ATR14 : 4.74, CCI20 : -47.70, Chaikin Money Flow : -0.03, MACD : -5.49, Money Flow Index : 36.72, ROC : 0.75, RSI : 38.37, STOCH (14,3) : 43.35, STOCH RSI : 1.00, UO : 43.59, Williams %R : -56.65), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Zoetis Inc. Class A in the last 12-months were: Abhay U. Nayak (Option Excercise at a value of $0), Catherine A. Knupp (Sold 10 000 shares of value $2 171 900 ), Glenn David (Option Excercise at a value of $2 515 017), Glenn David (Sold 32 390 shares of value $6 149 880 ), Gregory Norden (Option Excercise at a value of $0), Gregory Norden (Sold 4 500 shares of value $972 315 ), Heidi C. Chen (Option Excercise at a value of $1 383 650), Heidi C. Chen (Sold 18 892 shares of value $4 063 858 ), Kristin C. Peck (Option Excercise at a value of $1 050 260), Kristin C. Peck (Sold 39 000 shares of value $8 109 348 ), Linda Rhodes (Option Excercise at a value of $0), Louise M. Parent (Option Excercise at a value of $0), Michael B. McCallister (Option Excercise at a value of $0), Paul M. Bisaro (Option Excercise at a value of $0), Robert J. Polzer (Option Excercise at a value of $0), Roman Trawicki (Option Excercise at a value of $1 006 393), Roman Trawicki (Sold 14 989 shares of value $2 841 952 ), Roxanne Lagano (Option Excercise at a value of $879 715), Roxanne Lagano (Sold 41 545 shares of value $8 404 376 ), Willie M. Reed (Option Excercise at a value of $0), Willie M. Reed (Sold 1 450 shares of value $300 295 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
CEO: Kristin C. Peck
Telephone: +1 973 822-7000
Address: 10 Sylvan Way, Parsippany 07054, NJ, US
Number of employees: 11 300
Sat, 07 May 2022 01:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), BioCryst (BCRX) and McKesson (MCK)
- TipRanks. All rights reserved.Wed, 16 Feb 2022 13:17 GMT Analysts Are Bullish on These Healthcare Stocks: Zoetis (ZTS), SAGE Therapeutics (SAGE)
- TipRanks. All rights reserved.Wed, 16 Feb 2022 12:04 GMT Zoetis Q4 Earnings and Revenue Top Estimates Issues Guidance
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.